-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Annual Meeting of the European Society of Oncology (ESMO) is the most prestigious and influential oncology conference
background
Several studies have shown that first-line immunotherapy ± chemotherapy significantly improve overall survival (OS) compared with chemotherapymethod
Patients without driver gene mutations, poor PS (≥2), or patients with complications >70 years of age who are not eligible for locally advanced/metastatic NSCLC receiving platinum-containing dual-agent chemotherapy are included in the studyoutcome
A total of 453 patients were enrolled in the study and were randomly assigned to the altenizumab group (302 cases) and the chemotherapy group (151 casesconclusion
Regardless of histological type, PD-L1 expression, and ECOG PS score, first-line atenizizumab significantly improved OS (HR=0.78) unsuitable for platinum patients compared with chemotherapy, and the estimated number of patients who survived at 2 years of atenizumab treatment was twice as high as
chemotherapy.
Compared with chemotherapy, atenizumab was steadily associated with health-related quality of life and improved TTCDs
in patients.
Regardless of the subgroup, the IPSOS study was the first prospective study to show an improved prognosis of os in patients with poor prognosis in NSCLC, with no new adverse events and a guarantee of quality of life
。 References: LBA11-IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a Platinumcontaining regimen.
2022 ESMO.
Edit: Xiaoyuan Layout: Xiaoyuan Execution: Uni